David Sinclair’s ER-100 Clinical Trial: First Human Data on Glaucoma and Epigenetic Reprogramming

By Dr. Khanh Nguyen | October 18, 2026
Conceptual close-up of a human eye with abstract neural and molecular imagery representing vision and epigenetic research.

Protecting your vision means protecting the freedom to read, drive, travel, and enjoy the people and activities you love. That is why a new clinical trial in glaucoma is drawing attention far beyond eye care. On June 9, 2026, Life Biosciences, co-founded by Harvard Medical School geneticist Dr. David Sinclair, announced that the first participant…

Read More